Tower Research Capital LLC (Trc) Iveric Bio, Inc. Transaction History

Tower Research Capital LLC (Trc)

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $595,910 - $899,997	22,710 Added 468.83%	27,554 $1.08 Million
Q1 2023 May 09, 2023	BUY	$18.67 - $24.56 $64,691 - $85,100	3,465 Added 251.27%	4,844 $118,000
Q4 2022 Feb 10, 2023	SELL	$17.24 - $23.95 $126,127 - $175,218	-7,316 Reduced 84.14%	1,379 $30,000
Q3 2022 Nov 10, 2022	SELL	$9.4 - $18.59 $247,323 - $489,121	-26,311 Reduced 75.16%	8,695 $156,000
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $273,919 - $567,661	30,035 Added 604.2%	35,006 $337,000
Q1 2022 May 12, 2022	SELL	$12.15 - $16.83 $120,771 - $167,290	-9,940 Reduced 66.66%	4,971 $84,000
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $335,017 - $454,926	-24,224 Reduced 61.9%	14,911 $249,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $233,041 - $576,835	32,962 Added 533.97%	39,135 $636,000
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $16,574 - $20,886	2,913 Added 89.36%	6,173 $39,000
Q1 2021 May 17, 2021	SELL	$5.08 - $6.89 $8,458 - $11,471	-1,665 Reduced 33.81%	3,260 $21,000
Q4 2020 Feb 16, 2021	SELL	$5.65 - $7.66 $255,154 - $345,925	-45,160 Reduced 90.17%	4,925 $34,000
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $191,870 - $300,963	47,848 Added 2138.94%	50,085 $282,000
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $70 - $151	23 Added 1.04%	2,237 $11,000
Q1 2020 May 15, 2020	SELL	$2.83 - $8.44 $45,755 - $136,457	-16,168 Reduced 87.96%	2,214 $8,000
Q4 2019 Feb 07, 2020	BUY	$0.93 - $8.58 $16,952 - $156,404	18,229 Added 11914.38%	18,382 $158,000
Q3 2019 Nov 05, 2019	BUY	$1.09 - $1.29 $166 - $197	153 New	153 $0

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.